By LifETIME CDT Student: W. Sebastian Doherty-Boyd (University of Glasgow) During my PhD I will investigate the use of synthetic gels as a platform to grow and experiment on blood stem cells. The aim is to better understand the bone marrow (BM) niche where these cells reside, and search for causes and treatments of …
By lifETIME CDT Administrator: Emma Lardner (University of Birmingham) The Healthcare Technologies Institute at the University of Birmingham has received recognition for sustainable practices from the 2021 NUS Green Impact Awards; a United Nations award-winning programme designed to support environmentally and socially sustainable practice within organisations. The team was led by Emma Lardner, Operations Manager …
By LifETIME CDT Student: Sabah Sardar (University of Glasgow) My PhD project focusses on a rare gastrointestinal disorder called Visceral myopathy (VSCM). This disease mainly affects infants and young children. However, in some cases it can develop in adulthood. VSCM is a pathological disorder of the intestinal smooth muscle cells where there is a problem …
By LifETIME CDT Student: Matthew Woods (University of Glasgow) Stem cells are highly valuable in regenerative therapies because of their ability to change into several cell types. For example, mesenchymal stem cells can change into bone, cartilage or fat. When stem cells were first discovered it was thought that all the cells were identical, and all …
By LifETIME CDT Student: Sorour Nemati (NUI Galway) I am a chemical engineer whose ambition is to play a key role in human being life. Though it seems there is no specific role of chemical engineering in health care, its combination with other engineering streams such as biomedical engineering and biotechnology has introduced an …
By LifETIME CDT Student: Hannah Williamson (University of Birmingham) Cell therapies, medicines made from human cells, have had huge success in fighting leaukemias and offer new hope to patients as treatments for a range of diseases. However, the manufacture of these therapies remains a major challenge and barrier to patient access. New technologies are …